least one allele group of human leukocyte antigen (HLA)-A or human leukocyte antigen (HLA)-B.

18. The method of claim **17**, further comprising administering to said subject, at least 7 days after step b), a third pharmaceutical composition comprising allogeneic ASC of a third donor, wherein said third donor differs from both said first donor and said second donor in at least one allele group of HLA-A or HL A-B.

19. The method of claim **1**, wherein said ASC express a marker selected from the group consisting of CD73, CD90, CD29 and CD105.

20. The method of claim **19**, wherein said ASC do not express a marker selected from the group consisting of CD3, CD4, CD11b, CD14, CD19, and CD34.

21. The method of claim **19**, wherein said ASC do not express a marker selected from the group consisting of CD3, CD4, CD34, CD39, and CD106.

22. (canceled)

23. The method of claim **21**, wherein more than 50% of said ASC express CD200.

24. The method of claim **21**, wherein more than 50% of said ASC express CD141.

25. The method of claim **21**, wherein more than 50% of said ASC express SSEA4.

26. The method of claim **25**, wherein said ASC secrete Flt-3 ligand or stem cell factor (SCF).

27. The method of claim **1**, wherein the cells are administered intramuscularly.

28. The method of claim **1**, wherein the cells are administered intravenously, subcutaneously, or intraperitoneally.

* * * * *